Objectives The aim of this study was to explore discharge prescription rates of guideline-
directed medical therapy (GDMT), defined as aggregate antiplatelet agent, statin, and ACE …

Objective There is significant practice variation in the use of antithrombotic therapy after
endovascular intervention for lower limb peripheral arterial disease, with differences in …

Although intracranial hemorrhage (ICH) is frequent in the setting of brain metastases, there
are limited data on the influence of antiplatelet agents on the development of brain tumor …

Introduction Peripheral artery disease (PAD) is a major risk factor for cardiovascular
morbidity and mortality, despite surgical and endovascular treatments. Emerging evidence …

Introduction Peripheral artery disease (PAD) is a major risk factor for cardiovascular
morbidity and mortality, despite surgical and endovascular treatments. Emerging evidence …

After infrainguinal endovascular treatment for peripheral arterial disease (PAD), it is
uncertain whether single antiplatelet therapy (SAPT) or dual antiplatelet therapy (DAPT) …

Introduction To evaluate the efficacy and safety of paclitaxel‐coated balloon angioplasty in
the treatment of thrombosed arteriovenous fistulas. Methods This prospective, randomized …

Background: Antiplatelet therapy (APT) after interventions for lower extremity artery disease
(LEAD) is recommended. However,(inter) national guidelines vary on type and duration of …

To explore the application value of cross lesion pressure gradient testing in the
endovascular therapy for lower extremity arterial occlusive disease. A total of 73 patients …

Giannopoulos and Armstrong 537 or rivaroxaban, demonstrated the lower risk of MACE in
the combined group. 11, 12 However, the safety and efficacy of this antithrombotic approach …